Available in single doses and multipacks of 10 doses
Profile
AVAXIM® is an inactivated vaccine indicated for active immunisation against infection caused by the hepatitis A virus.
Before you prescribe this vaccine please refer to the SmPC.
AVAXIM is available in single doses and multipacks of 10 doses.
Why help protect your patients with AVAXIM® Vaccine?
- Hepatitis A remains one of the most common travel-related vaccine preventable diseases, although, the incidence in travellers is declining.1
- Hepatitis A is caused by a virus which is usually acquired through the consumption of food or water contaminated by human faeces. Foods such as undercooked meat and fish can be a risk as well as foods that grow close to the ground such as lettuce and strawberries. It can also be acquired through person to person contact.1
- The risk of acquiring hepatitis A is highest in low-income countries with poor sanitary conditions. Regions where hepatitis A is highly endemic include the Indian sub-continent (particularly Bangladesh, India, Nepal and Pakistan), Sub-Saharan and North Africa, parts of the Far East (except Japan), South and Central America and the Middle East.1
- There is no specific treatment for hepatitis A but risk can be reduced by following advice on food and water hygiene, and by ensuring good personal hygiene.1
Usage
Presentation |
0.5 ml prefilled syringe Available in 1 and 10 syringe packs |
Schedule | 1 dose |
Further dose | In order to provide long-term protection, a second dose (booster) of an inactivated hepatitis A vaccine should be given. The second dose is preferably given between 6 and 12 months but may be administered up to 36 months after the first dose |
Age range | 16 years + |
References
- Travel Health Pro. Hepatitis A. Available at https://travelhealthpro.org.uk/factsheet/21/hepatitis-a (Accessed October 2023).
MAT-XU-2301117 (v2.0) Date of preparation: October 2023